{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:32:59Z","timestamp":1790872379278,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd010497","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2015,8,10]],"date-time":"2015-08-10T00:00:00Z","timestamp":1439164800000}}],"reference-count":74,"publisher":"Wiley","issue":"2","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010497.pub2","type":"journal-article","created":{"date-parts":[[2015,8,10]],"date-time":"2015-08-10T13:18:10Z","timestamp":1439212690000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Oral fumaric acid esters for psoriasis"],"prefix":"10.1002","volume":"2017","author":[{"given":"Ausama","family":"Atwan","sequence":"first","affiliation":[{"name":"Cardiff University; Department of Dermatology & Wound Healing, Cardiff Institute of Infection & Immunity; 3rd Floor, Glamorgan House Heath Park Cardiff UK CF14 4XN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R","family":"Ingram","sequence":"additional","affiliation":[{"name":"Cardiff University; Department of Dermatology & Wound Healing, Cardiff Institute of Infection & Immunity; 3rd Floor, Glamorgan House Heath Park Cardiff UK CF14 4XN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Abbott","sequence":"additional","affiliation":[{"name":"University Hospital of Wales; Welsh Institute of Dermatology; Heath Park Cardiff UK CF14 4XW"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J","family":"Kelson","sequence":"additional","affiliation":[{"name":"Cardiff University; South East Wales Trials Unit, Institute of Translation, Innovation, Methodology and Engagement; Neuadd Meirionnydd Heath Park Cardiff Wales UK CF14 4YS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Pickles","sequence":"additional","affiliation":[{"name":"Cardiff University; South East Wales Trials Unit, Institute of Translation, Innovation, Methodology and Engagement; Neuadd Meirionnydd Heath Park Cardiff Wales UK CF14 4YS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bauer","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Carl Gustav Carus; Department of Dermatology; Fetscherstr. 74 Dresden Germany 01307"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Piguet","sequence":"additional","affiliation":[{"name":"Cardiff University; Department of Dermatology & Wound Healing, Cardiff Institute of Infection & Immunity; 3rd Floor, Glamorgan House Heath Park Cardiff UK CF14 4XN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,8,10]]},"reference":[{"issue":"6","key":"10.1002\/14651858.CD010497.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0190-9622(94)70121-0","article-title":"Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients","volume":"30","author":"Altmeyer","year":"1994","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD010497.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/j.1365-2133.2010.10195.x","article-title":"Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial","volume":"164","author":"Fallah Arani","year":"2011","journal-title":"British Journal of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD010497.pub2-BIB0003|cit3","first-page":"798","article-title":"Results of a phase II study of a novel oral fumarate, BG-12, in the treatment of severe psoriasis (Abstract P075). European Congress on Psoriasis 2004","volume":"18","author":"Langner","year":"2004","journal-title":"Journal of the European Academy of Dermatology & Venereology"},{"issue":"Suppl","key":"10.1002\/14651858.CD010497.pub2-BIB0004|cit4","first-page":"AB202","article-title":"Efficacy, safety, and quality of life effects of a novel oral formulation of dimethyl fumarate in patients with moderate to severe plaque psoriasis: Results of a phase 3 study","volume":"54","author":"Mrowietz","year":"2006","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD010497.pub2-BIB0005|cit5","first-page":"A69","article-title":"Dimethyl Fumarate (BG00012) as an Oral Therapy for Moderate to Severe Psoriasis: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (Abstract 406). 35th Annual ESDR Meeting 22-24th September 2005, T\u00fcbingen, Germany","volume":"125","author":"Mrowietz","year":"2005","journal-title":"Journal of Investigative Dermatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD010497.pub2-BIB0006|cit6","first-page":"187","article-title":"Results of a phase III study of a novel oral formulation of dimethylfumarate in the treatment of moderate to severe plaque psoriasis: efficacy, safety, and quality of life effects (Abstract P06.97). The 14th Congress of the European Academy of Dermatology and Venereology, London,UK. 12-15th October 2005","volume":"19","author":"Mrowietz","year":"2005","journal-title":"Journal of the European Academy of Dermatology & Venereology : JEADV"},{"key":"10.1002\/14651858.CD010497.pub2-BIB0007|cit7","unstructured":"Ortonne JP van de Kerkhof P Mrowietz U A novel oral agent improves quality of life (QOL) in patients with plaque psoriasis (Abstract P013) 4th European Association of Dermatology & Venereology (EADV) Spring Symposium. Saariselka, Lapland, Finland, Feb 9th-12th 2006 2006 P 013"},{"issue":"2 Pt 1","key":"10.1002\/14651858.CD010497.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0190-9622(08)80766-9","article-title":"Fumaric acid therapy for psoriasis: A randomized, double-blind, placebo-controlled study","volume":"22","author":"Nugteren-Huying","year":"1990","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"49","key":"10.1002\/14651858.CD010497.pub2-BIB0009|cit9","first-page":"2387","article-title":"Fumaric acid therapy in psoriasis; a double-blind, placebo-controlled study","volume":"134","author":"Nugteren-Huying","year":"1990","journal-title":"Nederlands Tijdschrift Voor Geneeskunde"},{"issue":"7","key":"10.1002\/14651858.CD010497.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1093\/rheumatology\/31.7.502","article-title":"Fumaric acid therapy for psoriatic arthritis. A randomized, double-blind, placebo-controlled study","volume":"31","author":"Peeters","year":"1992","journal-title":"British Journal of Rheumatology"},{"issue":"49","key":"10.1002\/14651858.CD010497.pub2-BIB0011|cit11","first-page":"2428","article-title":"Favourable effect of fumaric acid treatment in psoriatic arthritis: A double-blind placebo-controlled study","volume":"136","author":"Peeters","year":"1992","journal-title":"Nederlands Tijdschrift Voor Geneeskunde"},{"issue":"3","key":"10.1002\/14651858.CD010497.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/bjd.13277","article-title":"Addition of an oral histamine antagonist to reduce adverse events associated with fumaric acid esters in the treatment of psoriasis: a randomized double-blind placebo-controlled trial","volume":"172","author":"Balak","year":"2015","journal-title":"British Journal of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD010497.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1080\/000155501317208408","article-title":"Addition of pentoxifylline could reduce the side effects of fumaric acid esters in the treatment of psoriasis","volume":"81","author":"Friedrich","year":"2001","journal-title":"Acta Dermato-Venereologica"},{"issue":"1","key":"10.1002\/14651858.CD010497.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000063148","article-title":"Topical calcipotriol plus oral fumaric acid is more effective and faster acting than oral fumaric acid monotherapy in the treatment of severe chronic plaque psoriasis vulgaris","volume":"205","author":"Gollnick","year":"2002","journal-title":"Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD010497.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S0190-9622(89)70071-2","article-title":"Systemic therapy with fumaric acid derivates: New possibilities in the treatment of psoriasis","volume":"20","author":"Nieboer","year":"1989","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD010497.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000247856","article-title":"Fumaric acid therapy in psoriasis: a double-blind comparison between fumaric acid compound therapy and monotherapy with dimethylfumaric acid ester","volume":"181","author":"Nieboer","year":"1990","journal-title":"Dermatologica"},{"key":"10.1002\/14651858.CD010497.pub2-BIB0017|cit17","unstructured":"DRKS00000716 Regulatory T-cell function in psoriasis vulgaris apps.who.int\/trialsearch\/Trial2.aspx?TrialID=DRKS00000716"},{"key":"10.1002\/14651858.CD010497.pub2-BIB0018|cit18","unstructured":"EudraCT Number: 2012-000035-82 A 2:1 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of Fumaderm\u00ae in young patients aged 10 to 17 years with moderate to severe psoriasis vulgaris (KIFUderm study) www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-000035-82\/DE"},{"key":"10.1002\/14651858.CD010497.pub2-BIB0019|cit19","unstructured":"EudraCT Number: 2012-000055-13 A multi-center, randomized, double-blind, three-arm, 16 week, adaptive phase III clinical study to investigate the efficacy and safety of LAS41008 vs LASW1835 and vs Placebo in patients with moderate to severe plaque psoriasis www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-000055-13\/AT"},{"key":"10.1002\/14651858.CD010497.pub2-BIB0020|cit20","unstructured":"EudraCT Number: 2012-005685-35 A randomised, double blind, double dummy, active comparator and placebo controlled confirmative non-inferiority trial of FP187 compared to Fumaderm in moderate to severe plaque psoriasis www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number%3A2012-005685-35"},{"key":"10.1002\/14651858.CD010497.pub2-BIB0021|cit21","unstructured":"EudraCT Number: 2014-005258-20 A 24-week, randomized, controlled, multicenter, open-label study with blinded assessment of the efficacy of subcutaneous secukinumab compared to Fumaderm\u00ae in adults with moderate to severe plaque psoriasis www.clinicaltrialsregister.eu\/ctr-search\/trial\/2014-005258-20\/DE"},{"key":"10.1002\/14651858.CD010497.pub2-BIB0022|cit22","unstructured":"NCT00811005 Fumaric Acid Ester-PUVA Therapy Versus Acitretin -PUVA Therapy in Pustular Palmoplantar Psoriasis (FVSA-PUVA) www.clinicaltrials.gov\/show\/NCT00811005"},{"key":"10.1002\/14651858.CD010497.pub2-BIB0023|cit23","unstructured":"NCT01088165 The Influence of Adalimumab on Cardiovascular and Metabolic Risk in Psoriasis (CASTIP) www.clinicaltrials.gov\/show\/NCT01088165"},{"key":"10.1002\/14651858.CD010497.pub2-BIB0024|cit24","unstructured":"NCT01321164 Fumaric Acid Versus Fumaric Acid Plus Narrow Band Type B Ultraviolet (UVB) for Psoriasis www.clinicaltrials.gov\/ct2\/show\/NCT01321164"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010497.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000316177","article-title":"Methods of outcomes measurement in nail psoriasis","volume":"221","author":"Augustin","year":"2010","journal-title":"Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD010497.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1365-2133.1984.tb04678.x","article-title":"Epidermal T lymphocytes and HLA-DR expression in psoriasis","volume":"110","author":"Baker","year":"1984","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD010497.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/bjd.14500","article-title":"Efficacy, effectiveness and safety of fumaric acid esters in the treatment of psoriasis: a systematic review of randomized and observational studies","volume":"175","author":"Balak","year":"2016","journal-title":"British Journal of Dermatology"},{"issue":"12","key":"10.1002\/14651858.CD010497.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1111\/j.1365-4632.2010.04570.x","article-title":"The role of drugs in the induction and\/or exacerbation of psoriasis","volume":"49","author":"Basavaraj","year":"2010","journal-title":"International Journal of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD010497.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2165\/11533240-000000000-00000","article-title":"Dimethylfumarate for psoriasis: Pronounced effects on lesional T-cell subsets, epidermal proliferation and differentiation, but not on natural killer T cells in immunohistochemical study","volume":"11","author":"Bovenschen","year":"2010","journal-title":"American Journal of Clinical Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD010497.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1365-2133.2012.10835.x","article-title":"The British Association of Dermatologists' Biologic Interventions Register (BADBIR): design, methodology and objectives","volume":"166","author":"Burden","year":"2012","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD010497.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/09546630310019346","article-title":"Fumaric acid esters in the treatment of psoriasis: an Italian experience","volume":"15","author":"Carboni","year":"2004","journal-title":"Journal of Dermatological Treatment"},{"key":"10.1002\/14651858.CD010497.pub2-BIB0032|cit32","doi-asserted-by":"crossref","unstructured":"Ceglowska U Wlodarczyk A Slomka M Clinical effectiveness of fumaric acid esters (Fumaderm) in psoriasis: A systematic review of literature ISPOR 17th Annual European Congress Amsterdam, The Netherlands Nov 2014 PSS6","DOI":"10.1016\/j.jval.2014.08.2104"},{"issue":"3","key":"10.1002\/14651858.CD010497.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/0190-9622(93)70206-9","article-title":"Psoriasis in Australian twins","volume":"29","author":"Duffy","year":"1993","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"6729","key":"10.1002\/14651858.CD010497.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1136\/bmj.300.6729.908","article-title":"Clearance of severe psoriasis after allogenic bone marrow transplantation","volume":"300","author":"Eedy","year":"1990","journal-title":"BMJ"},{"issue":"7109","key":"10.1002\/14651858.CD010497.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"6","key":"10.1002\/14651858.CD010497.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1111\/j.1365-2133.2007.07881.x","article-title":"Psoriasis has a major secondary impact on the lives of family members and partners","volume":"156","author":"Eghlileb","year":"2007","journal-title":"British Journal of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD010497.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1038\/jid.2010.416","article-title":"Dimethylfumarate inhibits angiogenesis in vitro and in vivo: a possible role for its antipsoriatic effect?","volume":"131","author":"Garc\u00eda-Caballero","year":"2011","journal-title":"Journal of Investigative Dermatology"},{"issue":"11","key":"10.1002\/14651858.CD010497.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1084\/jem.20100977","article-title":"Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells","volume":"208","author":"Ghoreschi","year":"2011","journal-title":"Journal of Experimental Medicine"},{"issue":"40","key":"10.1002\/14651858.CD010497.pub2-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta4400","article-title":"A systematic review of treatments for severe psoriasis","volume":"4","author":"Griffiths","year":"2000","journal-title":"Health Technology Assessment"},{"issue":"9583","key":"10.1002\/14651858.CD010497.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"263\u201371","DOI":"10.1016\/S0140-6736(07)61128-3","article-title":"Pathogenesis and clinical features of psoriasis","volume":"370","author":"Griffiths","year":"2007","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD010497.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1365-2133.2005.06728.x","article-title":"Fumaric acid esters for severe psoriasis: a retrospective review of 58 cases","volume":"153","author":"Harries","year":"2005","journal-title":"British Journal of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD010497.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1365-2613.2009.00669.x","article-title":"Angiogenesis drives psoriasis pathogenesis","volume":"90","author":"Heidenreich","year":"2009","journal-title":"International Journal of Experimental Pathology"},{"key":"10.1002\/14651858.CD010497.pub2-BIB0043|cit43","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011 Available from www.cochrane-handbook.org"},{"issue":"2","key":"10.1002\/14651858.CD010497.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1046\/j.1365-2133.2003.05433.x","article-title":"Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis","volume":"149","author":"Hoefnagel","year":"2003","journal-title":"British Journal of Dermatology"},{"issue":"12","key":"10.1002\/14651858.CD010497.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1001\/archderm.143.12.1559","article-title":"Incidence and risk factors for psoriasis in the general population","volume":"143","author":"Huerta","year":"2007","journal-title":"Archives of Dermatology"},{"issue":"9","key":"10.1002\/14651858.CD010497.pub2-BIB0046|cit46","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010081","article-title":"Interventions for hidradenitis suppurativa","author":"Ingram","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD010497.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2165\/00128071-200506060-00005","article-title":"The psychosocial burden of psoriasis","volume":"6","author":"Kimball","year":"2005","journal-title":"American Journal of Clinical Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD010497.pub2-BIB0048|cit48","first-page":"170","article-title":"Fumaric acid and its derivatives in the treatment of psoriasis vulgaris: our experience in forty-one patients","volume":"17","author":"Kokelj","year":"2009","journal-title":"Acta Dermatovenerologica Croatica"},{"issue":"Suppl II","key":"10.1002\/14651858.CD010497.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/ard.2004.033217","article-title":"Psoriasis: epidemiology, clinical features, and quality of life","volume":"64","author":"Langley","year":"2005","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"9364","key":"10.1002\/14651858.CD010497.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/S0140-6736(03)12954-6","article-title":"Psoriasis","volume":"361","author":"Lebwohl","year":"2003","journal-title":"Lancet"},{"issue":"8","key":"10.1002\/14651858.CD010497.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1000\u20136","DOI":"10.1093\/eurheartj\/ehp567","article-title":"Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database","volume":"31","author":"Mehta","year":"2010","journal-title":"European Heart Journal"},{"issue":"6","key":"10.1002\/14651858.CD010497.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1038\/jid.2011.46","article-title":"Suppression of VEGFR2 expression in human endothelial cells by dimethylfumarate treatment: evidence for anti-angiogenic action","volume":"131","author":"Meissner","year":"2011","journal-title":"Journal of Investigative Dermatology"},{"issue":"9583","key":"10.1002\/14651858.CD010497.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0140-6736(07)61129-5","article-title":"Current and future management of psoriasis","volume":"370","author":"Menter","year":"2007","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD010497.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1046\/j.1365-2133.1999.03034.x","article-title":"Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. The German Fumaric Acid Ester Consensus Conference","volume":"141","author":"Mrowietz","year":"1999","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD010497.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.molmed.2004.11.003","article-title":"Dimethylfumarate for psoriasis: more than a dietary curiosity","volume":"11","author":"Mrowietz","year":"2005","journal-title":"Trends in Molecular Medicine"},{"issue":"3","key":"10.1002\/14651858.CD010497.pub2-BIB0056|cit56","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jtumed.2013.09.001","article-title":"Biologic systemic therapy for moderate-to-severe psoriasis: A review","volume":"8","author":"Mustafa","year":"2013","journal-title":"Journal of Taibah University Medical Sciences"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD010497.pub2-BIB0057|cit57","first-page":"S1","article-title":"S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update","volume":"10","author":"Nast","year":"2012","journal-title":"Journal der Deutschen Dermatologischen Gesellschaft"},{"issue":"5","key":"10.1002\/14651858.CD010497.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra0804595","article-title":"Psoriasis","volume":"361","author":"Nestle","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD010497.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/0895-4356(89)90168-6","article-title":"Meta-analysis in medical research: strong encouragement for higher quality in individual research efforts","volume":"42","author":"O'Rourke","year":"1989","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD010497.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/bjd.13128","article-title":"Regulated genes in psoriatic skin during treatment with fumaric acid esters","volume":"171","author":"Onderdijk","year":"2014","journal-title":"British Journal of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD010497.pub2-BIB0061|cit61","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence","volume":"133","author":"Parisi","year":"2013","journal-title":"Journal of Investigative Dermatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD010497.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-3083.2009.03389.x","article-title":"European S3-Guidelines on the systemic treatment of psoriasis vulgaris","volume":"23","author":"Pathirana","year":"2009","journal-title":"Journal of the European Academy of Dermatology & Venereology"},{"issue":"3 Pt 1","key":"10.1002\/14651858.CD010497.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0190-9622(99)70112-X","article-title":"Psoriasis causes as much disability as other major medical diseases","volume":"41","author":"Rapp","year":"1999","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD010497.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/sj.jid.5700996","article-title":"Dimethylfumarate reduces leukocyte rolling in vivo through modulation of adhesion molecule expression","volume":"128","author":"Rubant","year":"2008","journal-title":"Journal of Investigative Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD010497.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/bjd.12663","article-title":"Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials","volume":"170","author":"Schmitt","year":"2014","journal-title":"British Journal of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD010497.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/j.1365-2133.2006.07435.x","article-title":"Fumaric acid esters for severe psoriasis: the Leicestershire experience","volume":"155","author":"Sladden","year":"2006","journal-title":"British Journal of Dermatology"},{"issue":"7564","key":"10.1002\/14651858.CD010497.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1136\/bmj.333.7564.380","article-title":"Psoriasis and its management","volume":"333","author":"Smith","year":"2006","journal-title":"BMJ"},{"issue":"5","key":"10.1002\/14651858.CD010497.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1365-2133.2009.09505.x","article-title":"British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009","volume":"161","author":"Smith","year":"2009","journal-title":"British Journal of Dermatology"},{"issue":"8","key":"10.1002\/14651858.CD010497.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis & Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD010497.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/archderm.1992.01680110049004","article-title":"The role of streptococcal infection in the initiation of guttate psoriasis","volume":"128","author":"Telfer","year":"1992","journal-title":"Archives of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD010497.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/hmg\/6.5.813","article-title":"Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis","volume":"6","author":"Trembath","year":"1997","journal-title":"Human Molecular Genetics"},{"issue":"5","key":"10.1002\/14651858.CD010497.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/bjd.13098","article-title":"Fumaderm\u00ae in daily practice for psoriasis: dosing, efficacy and quality of life","volume":"171","author":"Walker","year":"2014","journal-title":"British Journal of Dermatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010497.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2133.2011.10280.x","article-title":"Cumulative life course impairment in psoriasis: patient perception of disease-related impairment throughout the life course","volume":"164","author":"Warren","year":"2011","journal-title":"British Journal of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD010497.pub2-BIB0074|cit74","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010497","article-title":"Oral fumaric acid esters for psoriasis","author":"Atwan","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD010497.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T23:10:23Z","timestamp":1748560223000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD010497.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Skin Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,8,10]]},"references-count":74,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,2]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010497.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,10]]}}}